Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects

NCT ID: NCT00987558

Last Updated: 2015-01-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-06-30
• Study Completion Date: 2009-08-31

Brief Summary

The primary objective was to investigate whether multiple-dose administration of ESL 800 mg once daily affects the pharmacokinetics of simvastatin, a substrate of CYP34A.

Detailed Description

This was a single centre, two-way crossover, randomised, open-label study in 24 healthy volunteers. The volunteers will receive an oral single-dose of simvastatin 80 mg on two occasions - once administered alone and once after treatment with an oral once-daily dose of 800 mg of ESL for 14 days -, separated by a washout period of 3 weeks or more

Conditions

Epilepsy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Sequence A

Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period

Group Type: EXPERIMENTAL

Eslicarbazepine acetate

Intervention Type: DRUG

Simvastatin

Intervention Type: DRUG

Treatment Sequence B

Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period

Group Type: EXPERIMENTAL

Eslicarbazepine acetate

Intervention Type: DRUG

Simvastatin

Intervention Type: DRUG

Interventions

Eslicarbazepine acetate

Intervention Type: DRUG

Simvastatin

Intervention Type: DRUG

Other Intervention Names

Zebinix; Zocor

Eligibility Criteria

Inclusion Criteria

• Male and female subjects aged 18 to 45 years, inclusive
• Body mass index (BMI) between 18 and 30 kg/m2, inclusive
• Healthy as determined by pre-study medical history, physical examination, vital signs, and 12-lead ECG; negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening; clinical laboratory test results clinically acceptable at screening and admission to each treatment period;
• Negative screen for alcohol and drugs of abuse at screening and admission to each treatment period
• Non-smokers or ex-smokers
• Able and willing to give written informed consent;
• If female, not of childbearing potential by reason of surgery or, if of childbearing potential, she uses one of the following methods of contraception: double barrier method: 1 male barrier method [male condom] plus 1 female barrier method (diaphragm, spermicide, or intrauterine device);
• If female, has a negative urine pregnancy test at screening and admission to each treatment period.

Exclusion Criteria

• Clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders
• Clinically relevant surgical history;
• History of relevant atopy or any drug hypersensitivity (including known hypersensitivity to ESL or other carboxamide derivatives, simvastatin or other statins or any of its excipients
• History of fibromyalgia, myopathy, rhabdomyolysis or unexplained muscle pain
• Second or third-degree atrioventricular blockade not corrected with a pacemaker or any other clinically significant abnormality in the 12-lead electrocardiogram (ECG) as determined by the investigator
• History of alcoholism or drug abuse
• Consume more than 14 units of alcohol a week
• Significant infection or known inflammatory process on screening or admission to each treatment period
• Acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period
• Use of medicines within two weeks of admission to first period that may affect the safety or other study assessments, in the investigator's opinion
• Have donated or received any blood or blood products within the 3 months prior to screening
• Vegetarians, vegans or have other medical dietary restrictions
• Cannot communicate reliably with the investigator
• Unlikely to co-operate with the requirements of the study
• Unwilling or unable to give written informed consent
• If female, is pregnant or breast-feeding
• If female, is of childbearing potential and does not use an approved effective contraceptive method (double-barrier method: 1 male barrier method [male condom] plus 1 female barrier method (diaphragm, spermicide, or intra-uterine device) or uses hormonal contraceptives
• Have received an investigational drug within 3 months of screening or is currently participating in another study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bial - Portela C S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marie Claude Homery, MD

Role: PRINCIPAL_INVESTIGATOR

Biotrial, 7-9, rue Jean-Louis Bertrand, F-35000 Rennes, France

Locations

Biotrial, 7-9 rue Jean-Louis Bertrand

Rennes, , France

Countries

France

Other Identifiers

BIA-2093-124

Identifier Type: -

Identifier Source: org_study_id